What Is Prescribed for Anxiety: SSRIs to Benzos

SSRIs and SNRIs are the most commonly prescribed first-line medications for anxiety disorders, recommended by virtually every major clinical guideline. Benzodiazepines, once the default choice, have been pushed into a more limited role because of dependence risks, though they remain widely used for short-term or acute relief. Between those two poles sits a surprisingly varied pharmacological landscape, including buspirone, beta-blockers, anticonvulsants, and antihistamines, each filling a different niche depending on the type of anxiety, the person’s history, and how quickly relief is needed.

SSRIs and SNRIs as the Standard Starting Point

When a clinician prescribes medication for generalized anxiety disorder, social anxiety disorder, or panic disorder, the first prescription is almost always an SSRI or an SNRI. Large network meta-analyses consistently rank drugs like escitalopram, duloxetine, and venlafaxine among the most effective options with relatively good tolerability.¹ A separate meta-analysis found duloxetine and escitalopram showed the best overall efficacy profile among first-line agents for generalized anxiety disorder specifically.²

The catch is timing. SSRIs and SNRIs do not work immediately. Most people need several weeks before they notice a meaningful reduction in anxiety, and during the first week or two, some actually feel worse. About 15% of patients in one study showed early worsening of anxiety symptoms during the first two weeks of SSRI treatment.³ This initial bump in anxiety is one of the main reasons people abandon the medication before it has a chance to help. Clinicians who anticipate this often start at a lower dose and increase gradually, or they prescribe a short course of a faster-acting drug alongside the SSRI to bridge the gap.

Common SSRIs prescribed for anxiety include sertraline, escitalopram, paroxetine, and fluoxetine, though not all perform equally well across every anxiety disorder. Fluoxetine, for example, did not separate from placebo for generalized anxiety in at least one network meta-analysis.² On the SNRI side, venlafaxine and duloxetine are the most established. SNRIs affect both serotonin and norepinephrine, which can be an advantage for people whose anxiety comes bundled with fatigue or chronic pain, but may also produce more side effects like elevated blood pressure or excessive sweating.

Benzodiazepines and the Speed-Versus-Risk Trade-Off

Benzodiazepines work fast. Drugs like alprazolam, clonazepam, lorazepam, and diazepam can reduce acute anxiety within thirty minutes to an hour. They do this by enhancing the activity of GABA, the brain’s primary inhibitory signaling chemical, which calms down overexcited neural circuits. For panic disorder in particular, high-potency benzodiazepines have proven efficacy and are sometimes used alongside SSRIs during the initial weeks of treatment to provide rapid relief while the SSRI ramps up.⁴

The problem is what happens when you try to stop. Physical dependence develops relatively quickly, and the withdrawal syndrome can be brutal. Common withdrawal symptoms include rebound anxiety and insomnia appearing within one to four days of stopping (depending on the drug’s half-life), along with irritability, tremor, sweating, difficulty concentrating, nausea, palpitations, headache, and muscle stiffness. A full-blown withdrawal syndrome typically lasts ten to fourteen days, though a third pattern exists where anxiety symptoms simply return and persist until another treatment is started.⁵ This makes it genuinely difficult for people to tell whether their anxiety is coming back or whether they are experiencing withdrawal, which is one reason benzodiazepine prescriptions can stretch from weeks into months and years.

Benzodiazepines were originally marketed in the 1960s for anxiety, stress, and insomnia, and they remain among the most widely used psychoactive drugs globally. Their cultural footprint is deep enough that diazepam (Valium) was famously referenced in the Rolling Stones’ 1966 song “Mother’s Little Helper.”⁶ Despite decades of warnings, they continue to be prescribed in situations where shorter-acting or less dependency-prone alternatives exist. One large network meta-analysis found benzodiazepines effective for generalized anxiety but poorly tolerated compared with placebo, largely because of sedation and withdrawal issues.¹

Buspirone and Why It Gets Overlooked

Buspirone occupies an odd place in anxiety treatment. It was the first non-benzodiazepine anxiolytic specifically developed for generalized anxiety disorder, and it works through an entirely different mechanism: partial agonism at the serotonin 5-HT1A receptor, with no interaction at the benzodiazepine receptor complex at all. That gives it a meaningfully better safety profile than benzodiazepines, with fewer sedation issues and essentially no dependence risk.⁷

So why isn’t it prescribed more? Partly because, like SSRIs, it takes weeks to reach full effect, and partly because people who have already experienced the immediate relief of a benzodiazepine often find buspirone underwhelming by comparison. It also does not help much with panic attacks or social anxiety, which narrows its useful range to generalized anxiety. But for someone with GAD who wants to avoid both SSRIs and benzodiazepines, buspirone is a legitimate option that deserves more attention than it typically gets. A Lancet meta-analysis found it efficacious and well tolerated, though the finding was limited by small sample sizes.¹

Beta-Blockers and Hydroxyzine for Situational Anxiety

Not all anxiety is chronic. Performance anxiety, for instance, involves a surge of adrenaline that produces shaking hands, a racing heart, dry mouth, and a quavering voice. Beta-blockers like propranolol target precisely those physical symptoms without sedation or cognitive dulling. In a double-blind study of professional musicians, propranolol eliminated the physical impediments to performance caused by stage fright, including dry mouth.⁸ Beta-blockers are now commonly used off-label by musicians, public speakers, and others facing situational performance demands. They do not reduce the mental sensation of nervousness as much as they prevent the body from broadcasting it, which in turn often reduces the mental component because you are no longer panicking about visible symptoms.

Hydroxyzine, an antihistamine with sedative and anxiolytic properties, fills another niche. It is sometimes prescribed for acute anxiety episodes when a clinician wants to avoid benzodiazepines, particularly in patients with a history of substance use. In one case report, a healthy man with an acute exacerbation of panic disorder was successfully treated with hydroxyzine at 25 mg twice daily, with rapid improvement of anxiety symptoms within 48 hours and no benzodiazepine use.⁹ That is a single case report, so it should not be read as strong evidence for hydroxyzine as a frontline panic treatment. But it illustrates how hydroxyzine gets used in practice: as a quick, low-risk tool when faster options like benzodiazepines are inappropriate.

Second-Line Options When First Choices Fail

If SSRIs, SNRIs, and buspirone all fail or cause intolerable side effects, prescribers have several further options, though the evidence gets thinner and the trade-offs sharper.

Pregabalin is approved for generalized anxiety in some countries (though not the United States, where it is approved for nerve pain and seizures). Randomized controlled trials and meta-analyses show it is effective for both acute treatment and relapse prevention in GAD, with some evidence of a faster onset of action than SSRIs. Its mechanism is different from most anxiety drugs: it binds to a specific subunit on calcium channels in overexcited neurons, reducing the release of excitatory brain chemicals like glutamate.¹⁰ The Lancet meta-analysis ranked pregabalin among the more efficacious and well-tolerated options for GAD alongside duloxetine, venlafaxine, and escitalopram.¹ Its downsides include sedation, dizziness, and weight gain, and it carries its own potential for misuse, especially at higher doses.

Quetiapine, an atypical antipsychotic, has also been studied for GAD. A meta-analysis of randomized trials found it significantly more effective than placebo, with response and remission rates about 24% and 27% higher, respectively. However, it came with a cost: the overall rate of people dropping out due to side effects was roughly double that of placebo, and only the 50 mg dose had tolerability comparable to SSRIs.¹¹ The Lancet analysis echoed this: quetiapine had the largest effect on anxiety scores of any drug studied but was poorly tolerated.¹ Because of metabolic side effects like weight gain and elevated blood sugar, quetiapine is generally reserved for people who have not responded to safer first-line agents.

Efficacy and Acceptability Do Not Always Line Up

A recurring theme in anxiety pharmacology is that the most powerful drug is not always the most tolerable. A 2025 network meta-analysis of 100 trials involving over 28,600 participants found that clomipramine (a tricyclic antidepressant) had the highest efficacy of all drugs studied, but it also led to the most study dropouts. By contrast, clobazam (a benzodiazepine) had the lowest dropout rate. Only four treatments in the analysis showed fewer adverse events than placebo: diazepam, agomelatine, clobazam, and silexan (a lavender oil preparation). Silexan was both highly effective and as acceptable as placebo, a combination that almost no other drug achieved.¹²

This disconnect matters because in real life, the drug that someone actually takes consistently is more useful than the theoretically stronger one they quit after two weeks. The SSRIs and SNRIs that dominate prescribing guidelines are not at the top of the efficacy rankings in every comparison. They sit in a middle zone where effectiveness, tolerability, and safety intersect well enough for most people. The “best” drug for any given person depends on which side effects they can live with, how fast they need relief, and whether they have risk factors that rule out certain classes entirely.

Special Populations and Altered Risk Calculus

The general prescribing hierarchy changes substantially for certain groups. In older adults, benzodiazepines become more dangerous because of their association with falls, cognitive impairment, sedation, and impaired driving ability, effects that are particularly pronounced with longer-acting formulations.¹³ Most geriatric prescribing guidelines advise against benzodiazepines as a routine treatment for anxiety in this age group.

For breastfeeding parents, the concern shifts to infant exposure. Most newer antidepressants produce very low or undetectable levels in nursing infants, but some are better studied than others. The highest infant blood levels have been reported for fluoxetine, citalopram, and venlafaxine, while paroxetine and sertraline are generally considered the most suitable first-line options during breastfeeding.¹⁴

In children and adolescents, the evidence supports SSRI and SNRI use for anxiety, with a meta-analysis showing a moderate treatment effect across trials. That same analysis found a trend toward increased “activation” (agitation or restlessness) with antidepressant treatment but no statistically significant increase in suicidality.¹⁵ Still, the black-box warning about suicidality risk in young people means these prescriptions tend to involve more monitoring and more careful conversations than they do in adults.

Combining Medication With Therapy

A question many people have is whether they should take medication, do therapy, or both. The answer depends partly on the disorder and partly on age. In children with anxiety disorders, a landmark trial found that combination treatment (sertraline plus cognitive behavioral therapy) led to improvement in about 81% of cases, compared with roughly 60% for therapy alone, 55% for sertraline alone, and 24% for placebo. The combination was superior to either treatment by itself.¹⁶

In adults, the picture is messier. A study comparing combined CBT plus venlafaxine to venlafaxine alone for generalized anxiety disorder found no significant difference between the groups on anxiety scores.¹⁷ That does not mean therapy is useless alongside medication in adults, but it does suggest the additive benefit is not always as clean as people assume. One interpretation is that for GAD specifically, either intervention on its own may push many patients toward their ceiling of improvement, leaving less room for the second to add benefit. For panic disorder and social anxiety, where avoidance behaviors play a larger role, therapy’s contribution to medication may be more distinct, though the evidence varies by study.

The Placebo Problem in Anxiety Trials

One complication that makes anxiety drug research hard to interpret is the large placebo response. A three-level meta-analysis of anxiety disorder trials found that the placebo response associated with SSRIs and SNRIs can be large enough to obscure the real benefits of the medication, since clinicians in practice cannot distinguish between improvements driven by the drug and those driven by the placebo effect.¹⁸ This does not mean the drugs are shams. It means that part of what makes any anxiety treatment “work” includes the act of seeking help, the structure of regular appointments, and the expectation of improvement. Medication adds a genuine pharmacological effect on top of that, but the margin can be narrower than people expect when they see a drug described as “effective.”

Why the Same Drug Works Differently in Different People

If you have ever been puzzled by someone else’s completely different experience with the same medication, genetics is part of the explanation. Liver enzymes called CYP2D6 and CYP2C19 metabolize many SSRIs, SNRIs, and other psychiatric medications. People who carry genetic variants that make these enzymes work faster or slower than average may end up with blood levels of a drug that are far above or below what the standard dose is designed to produce. Research suggests that people with non-standard CYP2D6 or CYP2C19 enzyme activity are more prone to both non-response and side effects from psychiatric medications.¹⁹ Pharmacogenomic testing, which checks for these variants through a cheek swab, is increasingly available and can help prescribers choose the right drug and dose more efficiently, though it is not yet routine in all practice settings.

Getting Off Anxiety Medication

Starting a medication gets most of the attention, but stopping one can be just as complicated. Benzodiazepine withdrawal has been recognized for decades, as described earlier, but SSRI and SNRI discontinuation problems took much longer to be formally acknowledged. The concept of “antidepressant discontinuation syndrome” was not introduced until 1997, and the UK Royal College of Psychiatrists did not formally acknowledge that withdrawal can be severe and long-lasting until 2019.²⁰ For years, patients reporting withdrawal symptoms were often told they were simply experiencing a return of their original anxiety, which led to frustration and unnecessary long-term prescriptions.

The practical takeaway is that tapering off any anxiety medication should be gradual and ideally supervised. The speed of the taper depends on the specific drug, the dose, and how long you have been taking it. Some patients need months of slow dose reductions. In the Netherlands, this reality gave rise to the development of “tapering strips,” which are individually compounded dose reductions packaged to make gradual discontinuation easier. If your prescriber suggests stopping a medication cold turkey, that is worth questioning, especially for benzodiazepines, paroxetine, and venlafaxine, all of which are known for more difficult discontinuation profiles.

Emerging Drugs and New Targets

The current anxiety medication toolkit has not changed dramatically in over two decades. SSRIs, SNRIs, benzodiazepines, and buspirone were all available by the late 1990s. The search for genuinely new treatments is focusing on different brain systems entirely. The glutamate system, neuropeptide signaling pathways, and the endocannabinoid system have all shown particular promise as future targets for novel anxiety drugs.²¹ Whether any of these pans out is uncertain, but the interest reflects a recognition that serotonin-based treatments, while helpful for many, leave a substantial minority of people without adequate relief. One recent meta-analysis’s finding that silexan (a standardized lavender oil extract) was both highly effective and well tolerated hints that some useful molecules may come from unexpected directions.¹² Silexan is available over the counter in some countries but has not been widely adopted in mainstream psychiatry, partly because its mechanism is still not fully understood and partly because herbal preparations face skepticism in clinical settings regardless of trial data.

1
The Lancet. Comparative efficacy and acceptability of pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis
2
PubMed. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis
3
PubMed Central. What Are the Clinical Implications of New Onset or Worsening Anxiety During the First Two Weeks of SSRI Treatment for Depression?
4
PubMed Central. The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder
5
PubMed. The benzodiazepine withdrawal syndrome
6
PubMed Central. Mother’s little helper? Contrasting accounts of benzodiazepine and methadone use among drug-dependent parents in the UK
7
The Internet Journal of Pharmacology. Buspirone And Anxiety Disorders: A Review With Pharmacological And Clinical Perspectives
8
PubMed. Effect of beta blockade and beta stimulation on stage fright
9
PubMed Central. Successful treatment with hydroxyzine of acute exacerbation of panic disorder in a healthy man: a case report
10
PubMed Central. Pregabalin for the treatment of generalized anxiety disorder: an update
11
PubMed Central. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials
12
PubMed Central. Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis
13
PubMed. Safety of benzodiazepines in the geriatric population
14
PubMed Central. Antidepressant Use During Breastfeeding
15
PubMed Central. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis
16
PubMed Central. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety
17
PubMed Central. Combined Medication and Cognitive Therapy for Generalized Anxiety Disorder
18
PubMed Central. Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan
19
PubMed. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication
20
PubMed Central. How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication
21
PubMed Central. Emerging drugs for the treatment of anxiety